Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer

Junyoung Choi1,2, Hee Jin Lee3, Shinkyo Yoon4, Hyun-Min Ryu1,2, Eunjin Lee1,2, Yujin Jo1, Seyoung Seo1, Deokhoon Kim4, Chang Hoon Lee5, Wanlim Kim6, Joo Young Ha7, Soo-Youl Kim8, Gyungyub Gong3, Kyung Hae Jung2, Sook Ryun Park1, Sang-We Kim1, Kang-Seo Park1,2, Dae Ho Lee1

1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea; 2 Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea; 3 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea; 4 Center for Cancer Genome Discovery, Asan Institute for Life Science, Asan Medical Center, Seoul 05505, Republic of Korea; 5 Bio & Drug Discovery Division, Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Republic of Korea; 6 Department of Orthopaedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea; 7 Division of Hematology/Medical Oncology, Department of Internal Medicine, Chung Ang University College of Medicine, Seoul 06973, Republic of Korea; 8 Tumor Microenvironment Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea

Received June 29, 2020; Accepted August 9, 2020; Epub September 1, 2020; Published September 15, 2020

Abstract: Anti-PD-1/PD-L1 immunotherapy, as a treatment for many tumors, has shown good efficacy. However, responses to immunotherapy did not always occur or last long, i.e. primary or acquired resistance, even tumors were PD-L1 positive. Several oncogenic pathways, including PI3K/AKT activation by PTEN loss and NF-kB activation, induce PD-L1 expression and PD-L1 inhibitor-resistance. They also induce expression of CCL2, an inhibitory chemokine that blocks T cell tracking into the tumor by binding to CCR2 on the T cell surface. In this study, we showed that transglutaminase 2 (TG2), a post-translational modification enzyme, induced ubiquitin-proteasome dependent degradation of tumor suppressors including PTEN and IκBα by peptide cross-linking, inducing CCL2 as well as PD-L1 expression via PI3K/AKT and NF-kB activation. It also induced PD-L1 inhibitor-resistance because CCL2 was expressed despite increased PD-L1, which was blocked by PD-L1 inhibitor. We also revealed that inhibition of TG2, instead of PD-L1, restored T cell-dependent killing effect by blocking expression of both PD-L1 and CCL2 in PD-L1(+) triple negative breast cancer (TNBC) cells. In addition, the TG2-expressing TNBC patient group showed higher PD-L1 expression incidence than did the TG2-negative TNBC patient group. In conclusion, TG2 induces primary PD-1/PD-L1 inhibitor-resistance by inducing CCL2 expression. TG2 blockade can be utilized as an excellent therapeutic strategy to overcome PD-L1 inhibitor-resistance in PD-L1(+) TNBC patients. Our study suggested that PD-L1 expression alone might not always be a predictive biomarker for PD-L1(+) TNBC, but TG2 could be a useful predictive marker to select PD-L1 inhibitor-resistant TNBC patients.

Keywords: Transglutaminase 2, TNBC, PD-1, PD-L1, drug resistance

Introduction

The immune checkpoint inhibitors (ICIs) eliminate cancer cells by restoring immune cell functions. The blockade of programmed death-protein 1 (PD-1) on the T cell surface and its co-inhibitory ligand (PD-L1) on the tumor surface enhances T cell immunity; hence, this process is considered one of the most successful cancer immunotherapy treatments. The binding of PD-L1 to PD-1 leads to T cell exhaustion. Thus, blockade of immune checkpoints, such as PD-1 and PD-L1, improves the therapeutic effect against cancers by maximizing cytotoxic T cell activity in the tumor microenvironment.

In the last decade, cancer immunotherapy using PD-1/PD-L1 inhibitors has spotlighted
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

Treatment of various tumors because no long-term therapeutic responses were observed on using standard cytotoxic anti-cancer agents.

Utilization of PD-L1 inhibitor in patients with different cancers, including melanoma [1], non-small cell lung cancer (NSCLC) [2], renal cell carcinoma (RCC) [3], Hodgkin’s lymphoma [4], bladder cancer [5], and head and neck squamous cell carcinoma (HNSCC) [6], has shown impressive clinical therapeutic effects. However, blockade of PD-1 and PD-L1 showed limitations in not only patients with low expression of PD-L1 but also those with high expression, demonstrating that the response rate to the inhibitors was only about 20% in most solid tumors. To overcome this limitation, we must understand the mechanisms of PD-1/PD-L1. In triple negative breast cancer (TNBC), objective response rates (ORRs) of PD-1/PD-L1 inhibitors were reportedly 20% in high PD-L1-expressed (+) tumors but less than 5% in lowly expressed or negative PD-L1(-) tumors. Some early responders with relapsed disease developed resistance to these therapies.

The several mechanisms of primary and acquired resistance to PD-1/PD-L1 inhibitors are well known. Representative mutations in STK11 and KEAP1 are associated with resistance to PD-1/PD-L1 blockade in NSCLC patients [7]. Currently, novel mechanisms of resistance to PD-1/PD-L1 blockade are being characterized, and new strategies are being suggested to overcome this resistance for improvement of patient outcomes.

As mentioned above, PD-L1 expression is currently utilized as a predictive biomarker to select anti-PD-1 or anti-PD-L1 therapy-sensitive patients [8]. PD-L1 immuno-histochemistry (IHC) is used as a representative predictive biomarker for various tumors including NSCLC and melanoma [9].

However, PD-1/PD-L1 inhibitor-resistant patients are still present even though these patients show PD-L1(+ ) tumors [10], indicating that PD-L1 is not the perfect biomarker to select patients for anti-PD-1/PD-L1 therapies. In fact, some patients with both PD-L1(+ ) and PD-L1(- ) tumors benefitted from PD-1/PD-L1 inhibitor treatment, but the benefit in PD-L1(+ ) patients was larger than that in PD-L1(- ) patients [2]. Recently, tumor mutation burden (TMB) was also utilized as an additional predictable biomarker to select patients applicable for PD-1/PD-L1 inhibitor treatment [11]. However, the prediction accuracy of TMB used in clinical studies is still controversial [12]. Therefore, identification of novel exact biomarkers that can predict PD-1/PD-L1 inhibitor response is required.

TNBC constitutes nearly 15-20% of all breast tumors, and is negative for estrogen receptors, progesterone receptors, and excess HER2 protein. This indicates that TNBC cannot be treated by hormone restriction therapy and usage of HER2 inhibitors, but chemotherapy can be used effectively [12].

Many clinical trials using several PD-1/PD-L1 inhibitors, such as atezolizumab and avelumab, had been conducted for PD-L1(+) TNBC patients, and some PD-1/PD-L1 inhibitors were approved by the FDA in 2019. Even though a higher ORR was seen in PD-L1(+) TNBC patients than in PD-L1(-) TNBC patients (22.2% vs. 2.6%) [13, 14], therapeutic effect of PD-1/PD-L1 inhibitors towards TNBC was low [15].

PD-L1 expression in the tumor is increased by activation of multiple oncogenic pathways and transcription factors, such as MYC, AP-1, STAT, IRF1, HIF, PI3K/AKT, and NF-κB [16]. Some oncogenic pathways contribute to PD-1/PD-L1 inhibitor-resistance. PTEN loss, which activates the PI3K/AKT pathway, induces PD-1 and PD-L1 inhibitor-resistance by promoting the release of anti-inflammatory cytokines that reduce infiltration and activation of CD8+ cytotoxic T cells in melanoma patients [17]. NF-κB activation usually increases not only inflammation through up-regulation of cytokines such as tumor necrosis factor (TNF)-α, but also immune response through activation of chemokines [18]. In contrast, NF-κB inhibition was reported to induce chemokine expression in lung adenocarcinoma [19]. In addition, NF-κB promotes angiogenesis and expression of anti-inflammatory cytokines in cancer patients [14, 20]. According to a recent study, activation of m-TOR, the downstream signal of the PI3K/AKT pathway, and NF-κB increased CCL2 expression and release, inducing recruitment of tumor-associated macrophages [21]. CCL2 is a chemokine that inhibits trafficking of cytotoxic T cells by binding with CCR2 of the T cell receptor [22]. Therefore, when CCL2 and PD-L1 are induced simultane-
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

Previously by PI3K/AKT and NF-κB activation, PD-1/PD-L1 inhibitor-resistance can occur due to release of CCL2, even though PD-L1 is completely blocked by the PD-L1 inhibitor.

Transglutaminase 2 (TG2) is a trans-peptidase, which is distributed widely in various tissues. It mediates cross-linking of proteins and participates in signal transduction by activating and hydrolyzing guanine triphosphate (GTP) enzyme. TG2 exerts diverse biological functions not only in normal tissues but also in both inflamed and cancer cells. TG2 is a multi-functional enzyme that demonstrates calcium dependent cross-linking activity and plays a vital role in inflammation mainly through modulation of the extracellular matrix (ECM) structure and stability. It also regulates tumor progression through these activities, attenuating cell adhesion and promoting ECM proteolysis. In normal breast tissues and those with benign hyperplasia, TG2 is rarely expressed, while in some breast cancer cells, TG2 expression is increased, contributing to tumor cell survival, invasion, and motility. In highly aggressive breast cancer cell lines, epithelial growth factor level is unimportant for migration and invasion but TG2 is already activated. Down-regulation of endogenous TG2 inhibits fibronectin-mediated cell attachment, survival, and invasion, while ectopic expression of TG2 augments attachment and invasion, suggesting that TG2 plays an important role in the development of metastases in breast cancer cells. TG2 causes cross-linking of the target molecule by transamidation, and the cross-linked target is then removed by ubiquitin-proteasome dependent degradation. Several tumor suppressors, including IκBα and PTEN, are target molecules of TG2 [23-26].

TG2-dependent IκBα and PTEN degradation induces PI3K/AKT and NF-κB activation, contributing to the use of chemotherapeutic agents, taxol and doxorubicin, and targeted drugs, such as EGFR-TKIs, in various tumors [27]. Interestingly, TG2 activates PI3K/AKT and NF-κB, which in turn, activate PD-L1. In addition, as mentioned above, PI3K/AKT and NF-κB activation by TG2 induces both PD-L1 and CCL2. Therefore, in this study, we investigated whether CCL2 release induced by PI3K/AKT and NF-κB activation led to PD-1/PD-L1 inhibitor-resistance, even though up-regulated PD-L1 was blocked by the PD-1/PD-L1 inhibitor. In addition, we investigated whether PD-L1 inhibitor-resistance could be restored by TG2 inhibition or co-inhibition of PD-L1 and CCL2 in PD-L1(+) TNBC patients. Therefore, in this study, we investigated the relationship between TG2 and PD-L1 and their cellular mechanisms and optimized the use of PD-1/PD-L1 inhibitors in TNBC patients based on the expression levels of TG2 and/or PD-L1.

Materials and methods

Cell culture and reagents

The human breast cancer cell lines, BT20, MCF7 and MDA-MB-231, were obtained from the American Type Culture Collection (Manassas, VA, USA). To obtain cultures, cells were incubated in RPMI-1640 culture medium supplemented with 10% fetal bovine serum (ThermoFisher Scientific, Waltham, MA, USA) at 37°C in an atmosphere of 5% CO₂. G9K21, TG2 inhibitor, was purchased from MedChemExpress (Monmouth Junction, NJ, USA) and dissolved in dimethyl sulfoxide to obtain a final concentration of 10 mM.

Transfection

To prepare a stable cell with overexpressed TG2, the pcDNA3.1/TG2 vector was transfected into the MCF7 cell using Lipofectamine® 2000 Reagent (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s protocol. MCF/TG2 cell was selected by G418 (500 µg/mL; Gibco, Carlsbad, CA, USA). To knockdown TG2 in the MDA-MB-231 cell line, we transfected short interfering RNA (siRNA) of TG2 (Sense: 5’-CCAAGUUCAUCAAGAACAUUU-3’, Anti-sense: 5’-AUGUUCUGAUGAACUUGGUU-3’), CCL2 (ThermoFisher Scientific, Waltham, MA, USA, AM51331), NF-κB p65 (#6261, Cell signaling, Danvers, MA, USA), and AKT (#6211, Cell signaling, Danvers, MA, USA) using Lipofectamine RNAiMAX Reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s protocol.

Western blot analysis

The harvested samples of the cells were lysed using RIPA buffer, which contained a protease inhibitor cocktail (Roche, Mannheim, Germany) and phosphatase inhibitor (1 mM sodium fluoride and 2 mM sodium orthovanadate). The
lysed protein samples were stored on ice for 30 min and then centrifuged at 13,000 × g for 30 min. The whole cell lysate was collected from the supernatant, and total protein was determined. The total protein (10-20 µg) was collected with 8-15% SDS-PAGE and then transferred to a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA, USA). After blocking with 10% skim milk in Tris buffered saline-tween (TBS-T), the membrane was allowed to react with the primary antibody at 4°C overnight and then horseradish peroxidase-conjugated secondary antibody (Bio-Rad, Hercules, CA, USA) in TBS-T, containing 1% bovine serum albumin, for 1 h at room temperature. The proteins were visualized using ECL Plus enhanced chemiluminescence reagents (Amersham Biosciences, Piscataway, NJ, USA) and G-box Chemi Systems (SynGene, Bangalore, India). TG2 antibody was purchased from ThermoFisher Scientific (CUB 7402, Waltham, MA, USA). The other antibodies, including AKT, phosphorylated (p)-AKT, PTEN, cleaved Caspase 3, cleaved Caspase 7, cleaved PARP, IκBα, PD-L1, and β-Actin were purchased from Cell Signaling Technology (Danvers, MA, USA).

Cell IHC

Breast cancer cells (1 × 10^3) were seeded on an eight-well chamber slide (MERCK, Frankfurt, Germany). After leaving it overnight, the supernatant was removed, and the cells were fixed with 4% formaldehyde for 20 min. After fixation, IHC was performed using Ultra-Sensitive ABC Peroxidase Staining kits (ThermoFisher Scientific, Waltham, MA, USA), according to the manufacturer’s protocol. The primary antibody on the fixed cells was stained with TG2 antibody (ThermoFisher Scientific, CUB 7402, Waltham, MA, USA) and PD-L1 antibody (Abcam, ab205921, Cambridge, United Kingdom), and the resultant samples were diluted to a concentration of 1 µg at 4°C overnight. Biotinylated secondary antibody and ABC Reagent were then sequentially added to the samples, and the resultant samples were allowed to react at room temperature for 30 min. Samples were then allowed to react with the substrate using AEC Substrate Chromogen (K3464; Dako, Carpinteria, CA, USA).

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from the breast cancer cells using Allprep DNA/RNA mini kits (Qiagen, Hiden, Germany), following the manufacturer’s protocol. Complementary DNA (cDNA) from total RNA samples was prepared using cDNA Reverse Transcription Kits (Applied Biosystems, Waltham, Massachusetts, USA), following the manufacturer’s protocol. The real-time quantitative analysis of the below-mentioned genes was performed with the LightCycler 480 System (Roche, Basel, Switzerland) and SYB Green real time PCR mix (TOYOBO, Osaka, Japan), following the manufacturer’s protocol. PD-L1 forward primer (5’-GCTATGTTGTCGCC-GACTAC-3’), PD-L1 reverse primer (5’-TGGCCTCCAGATTACCAAGT-3’), CCL2 forward primer (5’-AGATCTGTGTGACCCCCAAG-3’), and CCL2 reverse primer (5’-TCTTCCAGTTTGGTTTGCT-3’) were analyzed.

Jurkat T cell co-culture

Jurkat T cells were activated using Phorbol 12-myristate 13-acetate (PMA, 50 ng/mL) and Ionomycin (1 µg/mL) for 24 h. Breast cancer cells (5 × 10^5) were seeded on six-well plates. After leaving them overnight, siRNA transfection or drug treatment was performed. After 24 h of siRNA transfection or drug treatment, activated Jurkat T cells (3 × 10^6) were co-cultured with breast cancer cells. After 48 h, the supernatant was collected for harvesting the Jurkat T cells. PBS or free media washing was then performed three times thoroughly. Cancer cells or Jurkat T cells were harvested for western blot analysis and measurement of Caspase 3/7 by performing the Caspase-Glo 3/7 Luminescence Assay (Promega Corp. Madison, WI, USA). In order to make cancer cells alone remain on the each well, after co-culture with T cell and cancer cells, we conducted washing step with free media. As you know, T cells is suspended cells. As you can see in Supplementary Figure 1, most small suspended T cells are removed from attached cancer cells after three times washing step. Although some killed and suspended cancer cell are also removed in this washing step, this washing step makes damaged or killing cancer remain as attached status in the culture plate without suspended T cell.

Caspase 3/7 assay

Activated Caspase 3 and 7 were measured by performing the Caspase-Glo 3/7 Luminescence Assay (Promega Corp. Madison, WI, USA), fol-
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

following the manufacturers protocol. Protein samples from breast cancer cells or Jurkat T cells were prepared using RIPA buffer, in a manner similar to that for western blot sample preparation. Protein samples (10 µg), in a total volume of 100 µL, were transferred to white 96-well plates. Equilibrated Caspase-Glo 3/7 Reagent (100 µL) was added to the protein samples, and the resultant samples were incubated at room temperature for 1 h. Luminescence was measured using the Wallac 1420 apparatus (PerkinElmer, Waltham, MA, USA).

Interleukin-2 (IL2) and interferon gamma (IFNy) production assay

Jurkat T cells (1 × 10^7) were seeded on 6 well plates, and PMA (50 ng/mL) and Ionomycin (1 µg/mL) were added to activate the cells. The conditioned medium (CM) of the Jurkat T cells was harvested in a time-dependent manner to measure cytokines concentration. The CM was harvested and centrifuged at 2,000 rpm for 10 min to remove suspended cells, and each IL-2 and IFNγ concentration was measured using an IL-2 ELISA kit and IFNγ ELISA kit (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s protocol.

Immunohistochemistry

Serial sections (4 μm thickness) were mounted on glass slides coated with 10% polylysine. The sections were dewaxed in xylene and rehydrated in graded ethanol. The endogenous peroxidase activity was blocked by immersing the slides in 0.3% methanolic peroxide for 40 min. Immunoreactivity was enhanced by microwaving the tissue sections in 0.1 M citrate buffer for 10 min. Immunostaining was performed using the avidin-biotin-peroxidase complex method, and antigen-antibody reactions were visualized using chromogen diaminobenzidine. The TG2 and PD-L1 antibodies, used for IHC, were purchased from Sigma Aldrich (Limerick, PA, USA) and Cell Signaling Technology (Danvers, MA, USA), respectively. Overall staining intensity of the tissues was scored by a pathologist (Dr. Hee Jin Lee) using a scoring system of tumor cell staining intensity. A score of 0 indicated no staining of the tumor.

Immunocytochemistry

Cells seeded into 8-well glass (Millipore, 2.5 × 10^4 cells per well). The cells were fixed in 2% PFA (paraformaldehyde) at room temperature (RT) for 20 min. After treatment with blocking solution containing 5% FBS in PBS for 30 min, cells were stained with anti-human CD274 antibody (1:300; BioLegend, San Diego, California, USA, #329710) at 4°C overnight. Cells were washed three times with PBS and then stained with Alexa Fluor® 488 dye conjugated secondary antibody (1:2,000; Invitrogen, Carlsbad, CA, USA, A-21202) in the dark at RT for 1 hr. After cells were washed once with PBS, nuclei were stained with DAPI (1:1,000; Sigma Aldrich, Limerick, PA, USA, D9542) at RT for 5 min. All images were analyzed using ZEISS Axio Vert.A1 FL microscopy (Carl Zeiss, Oberkochen, Germany).

Flow cytometry

Cells were detached from tissue culture dish by TrypLE™ express (Gibco, Carlsbad, CA, USA). The cells were washed in FACS buffer containing 5% FBS (ThermoFisher Scientific, Waltham, MA, USA) in PBS. For immune staining, cells were resuspened in 100 ul of FACS buffer containing anti-human CD274 antibody (1:300; BioLegend, San Diego, California, USA, #329-710) at 4°C for 30 min. After washing twice in FACS buffer, cells were resuspened in 100 ul of FACS buffer containing Alexa Fluor® 488 dye conjugated secondary antibody (1:2,000; Invitrogen, Carlsbad, CA, USA, #A-21202) at 4°C for 20 min. Data was acquired using FACS CantoTM II (BD Biosciences, San Jose, CA, USA) and A total of 10,000 events were collected per sample. Analysis was performed using FACSDiva software v 8.0 (BD Biosciences, San Jose, CA, USA).

Cell viability test

Cell viability was measured using the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA) following the manual instructions. Approximately 3 × 10^4 cancer cells were plated to white 96 well plates. The next day, the culture medium was removed and the desired concentrations of drug or siRNAs were treated. After 24 h, activated Jurkat T cells (1 × 10^6) were co-cultured with cancer cells. After 72 hours, 100 µl of CellTiter-Glo reagent was added and the plates were incubated for 10 minutes at room temperature. The luminescence was measured using a Wallac 1420 apparatus (PerkinElmer, Boston, MA, USA). For testing cytokine effect in conditioned medium
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

(CM) of this co-culture, at 48 hr after adding of activated T cell in the wells, CM was harvested and centrifuged at 2,000 rpm for 10 min to remove suspended cells. CM were treated to each breast cancer cells, including MCF7/TG2 and MDA-MB-231, and after 72 hours, 100 μl of CellTiter-Glo reagent was added and the plates were incubated for 10 minutes at room temperature. The luminescence was measured using a Wallac 1420 apparatus (PerkinElmer, Boston, MA, USA).

Results

PD-L1 was an unpredictable biomarker of response to PD-1/PD-L1 inhibition

We first evaluated the activity of PD-1/PD-L1 inhibitor in selected PD-L1(+) TNBC cell lines, co-cultured with activated T cells, using avelumab (Figure 1). First of all, we selected one PD-L1(-) breast cancer cell (MCF7) and two PD-L1(+) breast cancer cells (BT20 and MDA-MB-231). PD-L1 expression and surface PD-L1 expression of each cells were evaluated by western blot (Figure 1A), Immunocytochemistry (Figure 1B) and FACS analysis (Figure 1C). We activated Jurkat T cells using PMA and ionomycin, as described in a previous study [28], and confirmed that activated Jurkat T cells induced PD-1 expression and IL-2 and IFNγ release (Figure 1D) [28]. Activated Jurkat T cells killed PD-L1(-) MCF7 cells (Figure 1E), but could not kill PD-L1(+) BT20 and MDA-MB-231 cells because PD-L1 binds to PD-1 on activated Jurkat T cells. In MCF7/TG2 cells, PD-L1 expression increased due to PI3K/AKT and NF-κB activation by TG2. Conversely, when TG2 was knocked-down in MDA-MB-231 cells, PD-L1 expression decreased due to blockade of AKT and NF-κB (Figure 2B-D). Even in the samples of 648 TNBC patients, the incidence of PD-L1 expression was much higher in TG2(+) TNBC samples than in TG2(-) TNBC samples (Figure 2E). These results suggested that PD-L1 could be induced by TG2-dependent signaling, involving PI3K/AKT and NF-κB activation.

TG2-induced PD-L1(+) TNBC cells showed PD-L1 inhibitor-resistance

Based on the finding that activated Jurkat T cells could not kill TG2(+) PD-L1(+) MDA-MB-231 cells (Figure 1), activity of Jurkat T cells in the above-mentioned four cell lines was evaluated, and we found that activated T cells could kill TG2 down-regulated cells but not TG2 up-regulated MCF7/TG2 and MDA-MB-231 cells (Figure 3A). We investigated whether TG2 inhibitor, GK921, could regulate PD-L1 expression in two TG2-induced PD-L1(+) TNBC cell lines, MCF7/TG2 and MDA-MB-231. GK921 decreased PD-L1 expression by restoring PTEN, blocking NF-κB activation, and inhibiting the PI3K/AKT pathway (Figure 3B). Using the co-cultures with activated Jurkat T cells, we observed that GK921 restored T cell-mediated apoptosis of TG2(+) MDA-MB-231 and MCF7/TG2 cells (Figure 3C and 3D). We have conducted MTS assay
Figure 1. PD-L1 is an unpredictable biomarker of response to PD-1/PD-L1 Inhibition. (A) PD-L1 mRNA and protein expression levels and (B and C) surface PD-L1 expression in MCF7, BT20, and MDA-MB-231 cells; (D) western blot analysis for PD-1 expression and ELISA assay for IL-2 and IFNγ levels in activated Jurkat T cells after PMA (50 ng/mL) and ionomycin (1 µg/mL) treatment; (E) Caspase 3/7 activity of PD-L1(-) MCF7 cells, co-cultured with activated Jurkat T cells; Caspase 3/7 activity of PD-L1(+) (F) BT20 and (G) MDA-MB-231 cells, co-cultured with activated Jurkat T cells, after treatment of PD-1/PD-L1 inhibitor for 24 h.
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

<table>
<thead>
<tr>
<th>Gene</th>
<th>Fold change [MDA-MB-231/BT20]</th>
</tr>
</thead>
<tbody>
<tr>
<td>TG2</td>
<td>14.60891089</td>
</tr>
</tbody>
</table>

Figure 2. TG2 induces PD-L1 expression by blocking PTEN and activating NF-κB in TNBC cells. (A) Fold change in TG2 in MDA-MB-231 and BT20 cells, and western blot analysis of TG2, PD-L1, PTEN, pAKT, and IκBα in MCF7 and MDA-MB-231 cells, with β-Actin as a loading control. (B) Western blot analysis of TG2, PD-L1, PTEN, pAKT, and IκBα in MCF7/Mock, MCF7/TG2, MDA-MB-231, and MDA-MB-231/TG2 siRNA cells, with β-Actin as a loading control. (C) Cell Immunohistochemistry and (D) FACS analysis for surface PD-L1 expression level in MCF7/Mock, MCF7/TG2, MDA-MB-231 and MDA-MB-231/TG2 siRNA. (E) Incidence of TG2 and PD-L1 expression in Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples of 648 TNBC patients.

(Supplementary Figure 2) as well to evaluate IFNγ-induced killing effect of activated Jurkat T cells. Like Caspase 3/7 assay, TG2 inhibitor (GK921), instead of PD-1/PD-L1 inhibitor, restored activated T cell-mediated killing effect (Supplementary Figure 2A and 2B). Especially, conditioned-media (CM) of co-culture condition with GK921 also directly killed cancer cells.
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

Figure 3. TG2-induced PD-L1(+) TNBC cells show PD-L1 inhibitor-resistance. (A) Expression levels of pAKT, pERK, cleaved Caspase 3, cleaved Caspase 7, PD-L1, and β-Actin in MCF7, MCF7/TG2, and MDA-MB-231 cells with or without activated Jurkat T cell co-culture, measured by western blot analysis; (B) western blot analysis to assess the expressions of TG2, PD-L1, PTEN, pAKT, IkBα, and β-actin in MCF7/TG2 and MDA-MB-231 cells after GK921 (TG2 inhibitor) treatment for 24 h in a dose-dependent manner; (C) western blot analysis and (D) Caspase 3/7 activity assay performed using protein samples from MCF7/TG2 and MDA-MB-231 cells, co-cultured with activated Jurkat T cells, after GK921 treatment for 24 h; (E) western blot analysis and (F) Caspase 3/7 activity assay implemented using protein samples from MCF7/TG2 and MDA-MB-231 cells, co-cultured with or without activated Jurkat T cells for 24 h, after siRNA transfection of p65, AKT, or TG2 for 24 h.
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

because CM includes IFNγ by activated Jurkat T cells (Supplementary Figure 2A and 2B). Suspended cells in CM are removed by centrifuge before treatment. However, we also found that blocking AKT or p65, a downstream signal, was not sufficient to restore sensitivity to T cell immunity (Figure 3E and 3F). These results suggested that TG2 inhibitor or the blocking-signal pathway, instead of the blocking PD-1/PD-L1 interaction, could restore cancer-killing T cell immunity if the initiating mechanism that induced PD-1/PD-L1 expression was known.

CCL2 induction by TG2 contributed to PD-L1 inhibitor-resistance via regulation of negatively cytotoxic T cells in TNBC cells

The mechanism of induction of PD-1/PD-L1 remains unknown. Therefore, we explored the mechanism that could be involved in intrinsic resistance to PD-1/PD-L1 inhibitors. Among the many T cell associated chemokines including endothelin-1, CCL2, CCL3, fractalkine, CXCL9/10/11, CCL4/5, CCL20, S1P, and CXCL-16, CCL2 was checked, and based on recent findings, we found that CCL2 expression was increased by mTOR, the downstream signal of PI3K/AKT, and NF-κB [21]. CCL2 is a well-known chemokine that binds to the T cell receptor CCR2 to reduce T cell activation and inhibit cytotoxicity of T cells [22]. Fortunately, we found that only TG2-induced PD-L1(+) breast cancer MDA-MB-231 and MCF7/TG2 cells showed high CCL2 expression. Interestingly, low CCL2 expression was observed in the BT20 cell line, which also showed low expression of TG2 and relatively high expression of PD-L1 and could be killed by activated Jurkat T cells. CCL2 was not expressed in TG2(-)/PD-L1(-) MCF7 cells (Figure 4A-C). When TG2 was knocked-down or down-regulated by TG2 siRNA, both PD-L1 and CCL2 expression levels greatly decreased (Figure 4D), demonstrating that CCL2 expression was also TG2-dependent. We then confirmed that CCR2 expression increased in the activated Jurkat T cells (Figure 4E). To investigate whether co-inhibition or dual blockade of CCL2 and PD-L1 could overcome intrinsic resistance to PD-1/PD-L1 inhibition, we down-regulated CCL2 expression using siRNA and added PD-L1 inhibitor, avelumab, to MCF7/TG2 and MDA-MB-231 cells. Then, by performing western blot analysis and Caspase 3/7 assay, we observed that dual blockade of CCL2 by siRNA and PD-L1 by avelumab restored T cell-mediated apoptosis of TG2-induced PD-L1(+) TNBC MDA-MB-231 and MCF7/TG2 cells. The dual blockade of CCL2 and PD-L1 showed more apoptosis than did blockade of either CCL2 by siRNA or PD-L1 by avelumab (Figure 4F and 4G).

Discussion

PD-1/PD-L1 inhibitors have recently gained attention, and are being used as major cancer treatments in patients with various cancers. However, some cancer patients show intrinsic resistance to PD-1/PD-L1 inhibitors even though the tumor cell surfaces express PD-L1. In recent years, evidence on the prognostic effects of PD-L1 expression, which causes immune evasion of tumor, on TNBC has been revealed [30]. Therefore, the effective therapeutic approaches using ICIs, such as PD-1/PD-L1 inhibitors, are being continuously tested for treatment of TNBC. Over the last year, novel and significant evidence on the perfection of immune checkpoint-based treatments in TNBC, based on the results of the IMpassion130 trial, has been revealed, driving breast cancer into the immunotherapy age [31]. In addition, interestingly, PD-L1 expression assessment of immune cells in tumors also utilizes a novel CDx marker for PD-L1 expression on the tumor cell surface [31]. In the Impassion130 biomarker subgroup analysis [32], PD-L1 expression in immune cells positively correlated with the CD8+ T cell number in the tumor. This result implicated that PD-L1 expression in both tumor and immune cells should be assessed to select PD-1/PD-L1 inhibitor-sensitive TNBC patients.

Several PD-1/PD-L1 inhibitors selectively inhibit PD-L1 interaction with PD-1 or B7-1 (a co-stimulatory cell-surface protein), relieving T-cell suppression. Some of the inhibitors have already been approved for the treatment of melanoma [33] and NSCLC [9], and have shown good treatment effects with a safety profile in patients with other solid tumors [1, 6], including TNBC [34].

However, in another clinical trial, only a few TNBC patients showed a response to PD-1/PD-L1 inhibitor because the number of PD-L1(+) TNBC patients was low [15] and some of them showed intrinsic resistance to PD-1/PD-L1 inhibitors.
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

Therefore, the effective therapeutic approaches of ICIs in TNBC have been continuously researched. However, as with patients with other carcinomas, only a few TNBC patients showed effective intrinsic resistance. In particular, when PD-L1 inhibitor was provided alone in PD-L1(+) TNBC patients, ORR of avelumab was 5.2% and of atezolizumab was about 10%, indicating a very low response [13]. This indicated that PD-L1 expression alone was an unpredictable marker to select patients that are applicable for PD-1/PD-L1 inhibitor treatment.

Figure 4. CCL2 induction by TG2 contributes to PD-L1 inhibitor-resistance via regulation of negatively cytotoxic T cells in TNBC cells. The level of (A) PD-L1 and (B) CCL2 mRNA expression in MCF7, BT20, MCF7/TG2, and MDA-MB-231 cells measured by qRT-PCR analysis; (C) western blot analysis to check expression levels of TG2, P-AKT, IκBα, PD-L1, CCL2, and β-Actin in MCF7, BT20, MCF7/TG2, and MDA-MB-231 cells; (D) the expression of TG2, PD-L1, and CCL2 in MCF7/TG2 and MDA-MB-231 cells tested by western blotting analysis after TG2 siRNA transfection; (E) expression of PD-1 and CCR2 in Jurkat T cells with or without treatment of PMA (50 ng/mL) and ionomycin (1 µg/mL) for 24 h measured by western blotting; (F and G) the protein levels of cPARP, IκBα, PD-L1, and CCL2 in MCF7/TG and MDA-MB-231 cells with or without activated Jurkat T cell co-culture for 24 h measured by western blotting after CCL2 siRNA transfection, Avelumab (20 µg/mL) treatment, or dual combination treatment and Caspase 3/7 activity measured by Caspase 3/7 assay using proteins from MCF7/TG and MDA-MB-231 cells.
Recently, combined treatment of chemotherapy and PD-L1 antibody therapy has been widely used in TNBC patients with FDA approval [35]. In particular, the combination treatment of Nab-paclitaxel and atezolizumab shows a very high treatment rate with 56% ORR in PD-L1(+) TNBC patients [36]. However, many critical targets and mechanisms of inducing immunotherapy resistance remain unclear. Therefore, many studies on the mechanism of intrinsic resistance of immunotherapy agents are being actively conducted to uncover predictive markers and therapeutic targets, and instead of PD-L1 expression, multifarious potential biomarkers including tumor infiltrating lymphocytes (TILs), TMB, microsatellite instability (MSI), and mismatch repair (MMR) deficiency are now being assessed worldwide to predict exact immunotherapeutic efficacy in breast cancer.

Recently, the importance of TILs has attracted attention due to rise in the concept of “hot tumor” and “cold tumor” in relation to immunotherapy resistance. “Hot tumor” is a tumor that shows a very high response rate to ICIs, a high rate of T cell infiltration, and an interferon signature. In contrast, “cold tumor” refers to low immune infiltration and low response rate to ICIs [37]. In TNBC patients that are treated with combined atezolizumab and nab-paclitaxel, higher PD-L1 expression and CD8+ cytotoxic T cell infiltration indicate higher progression free survival (PFS) and overall survival (OS) [37]. Therefore, low infiltration of cytotoxic T cells and a low immunogenic tumor micro-environment are emerging as important causes of immunotherapy resistance. Indeed, several studies have reported them to cause resistance to ICIs by inhibiting priming and trafficking of T cells [38]. In particular, chemokine release by several oncogenic pathways is one of the major mechanisms that cause ICI resistance by inactivating cytotoxic T cells. Among the pathways, PI3K/AKT activation by PTEN loss is the most representative of ICI resistance. When PTEN loss occurs, the expression of immunosuppressive cytokines, such as VEGF, increases, in turn causing immunotherapy resistance by inhibition of T cell activity and trafficking of cytotoxic T cell tracking towards the tumor [17]. NF-κB activation increases the expression of immunosuppressive cytokines such as VEGF or TGF-beta [14, 20]. A recent report revealed that CCL2 expression increased by activation of both mTOR, the downstream protein of the PI3K/AKT pathway, and NF-κB [21]. Unlike other chemokines, CCL2 is the chemokine that inhibits cytotoxic T cell activity by binding to the T cell receptor CCR2 [22]. In addition, PI3K/AKT and NF-κB activation are oncogenic pathways that increase PD-L1 expression in tumors [38].

Therefore, even if the binding of PD-L1 with PD-1 is effectively blocked by PD-1/PD-L1 inhibitors, increased CCL2 expression by PI3K/AKT and NF-κB activation may lead to PD-1/PD-L1 inhibitor-resistance by inhibition of cytotoxic T cell tracking towards the tumor.

CCL2 induces recruitment of macrophages in the tumor [39]. According to a recent research, macrophages reduce the effect of the PD-1/PD-L1 inhibitor by delaying infiltration of T cells, such as CD8+ cytotoxic T cells, in the tumor [40]. Therefore, the increase in macrophage recruitment by CCL2 is likely to induce resistance to immunotherapy by reducing infiltration of cytotoxic T cells into the tumor. Thus, CCL2 is considered an important target in cancer immune-treatment because it not only promotes cancer growth by angiogenesis in the tumor microenvironment, but also reduces infiltration of cytotoxic T cells, reducing the efficiency of immunotherapy treatment.

Indeed, we don’t know whether activated Jurkat T cell effect is antigen or MHC dependent. In this study, we focused IFNy-induced killing effect of activated Jurkat T cell. In Figure 1D, we showed cytokines, including IL2 and IFN gamma (IFN-γ), release by activation of T cells. Especially, IFN-γ is well known to decrease tumor growth by acting not only directly on cancer cells via STAT1 activation, but also indirectly on endothelial cells and immune cells in the tumor microenvironments [41]. Therefore, we have conducted MTS assay (Supplementary Figure 2) as well as Caspase-3/7 assay (Figure 3) to evaluate IFNy-induced killing effect of activated Jurkat T cells. Especially, conditioned media (CM) of co-culture condition also directly killed cancer cells because CM includes IFNy by activated Jurkat T cells (Supplementary Figure 2). Suspended cells in CM are removed by centrifuge.

TG2 is a calcium-dependent multifunctional enzyme, and is overexpressed in many cancers [26]. In fact, TG2 is an oncogene that contrib-
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

Figure 5. Diagrams illustrate the mechanisms of action of TG2 in intrinsic resistance to PD-1/PD-L1 inhibitors. (A) High TG2 expression induces CCL2 and PD-L1 in TNBC cells via PI3K/AKT and NF-κB activation pathways. (B) Therefore, TG2-induced PD-L1(+) TNBC patients cannot be treated with PD-1/PD-L1 inhibitors, and show intrinsic PD-1/PD-L1 inhibitor-resistance because TG2-induced CCL2 negatively regulates cytotoxic T cells despite complete blockade of binding of PD-L1 with PD-1 by PD-1/PD-L1 inhibitor. In conclusion, (C) TG2 inhibition or (D) dual inhibi-
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC (TG2(+)/PD-L1(+) TNBC patients. In addition, TG2 can be used as a novel CDx marker to select PD-1/PD-L1 inhibitor-resistant patients in a clinical set-up.

In this study, we proved that intrinsic PD-1/PD-L1 inhibitor-resistance was induced by TG2 in TNBC cells. As mentioned in the results, we presented that TG2 was highly expressed in PD-L1(+) TNBC cell lines and confirmed that PD-L1 expression increased due to both PI3K/AKT and NF-κB activation by TG2.

In clinical practice, the correlation between TG2 and PD-L1 expression was also confirmed through a higher incidence of PD-L1 expression in TG2(+) TNBC patients than in TG2(-) TNBC patients. In addition, PD-L1 inhibitor-resistance was only exhibited in TNBC cell lines with high TG2 and PD-L1 expression levels. If the initiating molecule that induces immune escape (TG2 in this study) is known, we can use an agent that targets the molecule (TG2 inhibitor) to restore T cell immunity in tumor cells. Among the 648 clinical samples tested in this study, we found 12 TNBC patients (1.8%) who co-expressed both TG2 and PD-L1.

 Taken together, our results suggested that PD-L1 and CCL2 expression could be increased simultaneously by the TG2-dependent PTEN/NF-κB and PI3K/AKT signaling pathways. In this case, even if PD-L1 was blocked by PD-1/PD-L1 inhibitor, intrinsic resistance to PD-1/PD-L1 inhibitors could occur by weakening cytotoxicity of T cells via TG2-induced CCL2 activation (Figure 5). Above all, PD-1/PD-L1 inhibitor-resistant individuals among PD-L1(+) TNBC patients could be selected based on their TG2 expression level, which was found to be a novel companion diagnostic marker, and these patients could benefit by overcoming intrinsic PD-1/PD-L1 inhibitor-resistance via "TG2 inhibition alone" or "dual inhibition of PD-L1 and CCL2 by TG2-induced immune suppressors" (Figure 5). In addition, our findings suggest that TG2 can be used as a novel exact CDx marker to select intrinsic PD-1/PD-L1 inhibitor-resistant PD-L1(+) TNBC patients.

Acknowledgements

This manuscript was supported the Post-Genome Technology Development Program [10067-758, Business model development driven by clinico-genomic database for precision immuno-oncology] funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea) and the Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. NRF-2017 R1D1A1B03033550) and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2018M3A-9E2024004) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2020R1A2C10-12506).

Disclosure of conflict of interest

Dae Ho Lee declares honorary from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CJ Healthcare, ChongKunDang, Eli Lilly, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm, and ST Cube. The other authors declare that they have no conflict of interest.

Address correspondence to: Dr. Dae Ho Lee, Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea. Tel: +82-2-3010-3214; Fax: +82-2-3010-6961; E-mail: leedaeho@amc.seoul.kr; Dr. Kang-Seo Park, Department of Biomedical Sciences, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. Tel: +82-2-3010-8454; Fax: +82-2-3010-2265; E-mail: 77kangseo@gmail.com; kpark@amc.seoul.kr
TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC

References


TG2 induces intrinsic PD-1/PD-L1 inhibitor resistance in TNBC


Supplementary Figure 1. Distinguish between attached cancer cells and suspended Jurkat T cells by washing steps in co-culture system.

Supplementary Figure 2. The killing effect by TG2 inhibitor in co-culture system. Cell viability was measured using the CellTiter-Glo luminescent cell viability assay. MTS assay (Supplementary Figure 2) of MCF7/TG2 (A) and MDA-MB-231 (B), as well as Caspase-3/7 assay (Figure 3), have conducted to evaluate IFNγ-induced killing effect of activated Jurkat T cells. Especially, each conditioned-media (CM) from co-culture condition also directly killed cancer cells because CM includes IFNγ by activated Jurkat T cells. Suspended cells in CM are removed by centrifuge step.